ORIGINAL ARTICLE

Association between genetic risk scoring for schizophrenia and bipolar disorder with regional subcortical volumes

X Caseras¹, KE Tansey¹,², S Foley¹,³ and D Linden¹,³

Previous research has shown coincident abnormal regional brain volume in patients with schizophrenia (SCZ) and bipolar disorder (BD) compared with controls. Whether these abnormalities are genetically driven or explained by secondary effects of the disorder or environmental factors is unknown. We aimed to investigate the association between genetic risk scoring (GRS) for SCZ and BD with volume of brain areas previously shown to be different between these clinical groups and healthy controls. We obtained subcortical brain volume measures and GRS for SCZ and BD from a sample of 274 healthy volunteers (71.4% females, mean age 24.7 (s.d. 6.9)). Volume of the globus pallidus was associated with the shared GRS between SCZ and BD, and also with the independent GRS for each of these disorders. Volume of the amygdala was associated with the non-shared GRS between SCZ and BD, and with the independent GRS for BD. Our results for volume of the globus pallidus support the idea of SCZ and BD sharing a common underlying neurobiological abnormality associated with a common genetic risk for both these disorders. Results for volume of the amygdala, though, would suggest the existence of a distinct mechanism only associated with genetic risk for BD. Finally, the lack of association between genetic risk and volume of most subcortical structures suggests that the volumetric differences reported in patient–control comparisons may not be genetically driven, but a consequence of the disorder or co-occurring environmental factors.

Translational Psychiatry (2015) 5, e692; doi:10.1038/tp.2015.195; published online 8 December 2015

INTRODUCTION

Recent neuroimaging research has shown bipolar disorder (BD) to be associated with brain structural abnormalities. Different meta-analytical efforts have shown presence of enlarged lateral ventricles andglobus pallidus and reduced prefrontal volume in BD patients compared with healthy controls.¹⁻³ More recently, the ENIGMA (Enhancing Neuroimaging Genetics through Meta-Analysis) consortium has performed the largest study of subcortical brain volumes in BD to date—over 1500 patients and 2500 controls—replicating the enlargement of lateral ventricles in patients with BD, but not of the globus pallidus, and also reporting decreased volume of the thalamus, amygdala and hippocampus.⁴

Overlapping results have been reported in structural brain imaging studies of schizophrenia (SCZ). In a meta-analysis of 58 studies, Wright et al.⁵ found evidence in SCZ for enlarged lateral ventricles and globus pallidus, and reduced volume of amygdala, hippocampus, thalamus and caudate. The ENIGMA consortium, with a sample of over 2000 cases and controls, also reported enlarged lateral ventricles and globus pallidus, and reduced volumes of amygdala, hippocampus, thalamus and accumbens.⁶

Fewer studies have compared participants diagnosed with BD and SCZ directly, but the results of those point again towards a very important coincidence in subcortical and cortical gray matter abnormalities between both disorders, with SCZ being associated with more extensive abnormalities and greater effect sizes.⁷⁻⁹ and therefore suggesting the differences between both these disorders being quantitative rather than qualitative. This correspondence in brain anatomical abnormalities is not surprising considering the important overlap between both disorders in terms of clinical presentation and associated cognitive deficits.⁹,¹⁰ Moreover, recent genetic research has also highlighted a substantial overlap in common genetic variation associated with both disorders.¹¹,¹² These results question the classical division set by Kraepelin more than a century ago between the two types of psychosis, suggesting that both disorders might represent the same underlying neurobiological mechanisms.

However, whether the aforementioned anatomical abnormalities predate the onset of the disorder, are a consequence of it, or perhaps reflect pharmacological effects of the treatment that these patients commonly receive, is a key question that remains unanswered. It is frequently assumed that if predating the disorder, these abnormalities would arise from genetic factors, but it could also be the case that they reflect exposure to environmental factors that contribute to both disorders. To address this issue, some studies have included non-affected relatives of BD and SCZ patients in their design.¹³⁻¹⁵ Here, the premise is that the unaffected relatives of people with the disorder are at higher genetic risk than the population average but are not subject to secondary effects of the disorder itself (including its treatment). Consequently, if the unaffected relatives have similar abnormalities to cases, it can be concluded that these are more likely to be genetically driven than environmentally or pharmacologically caused. However, to date these studies have mostly failed to replicate the aforementioned coincidence in
anatomical abnormalities between SCZ and BD, most likely due to their smaller sample sizes and the consequent limitation in statistical power.

Developments in genetics have recently allowed a new method for investigating the relationship between genetic risk and brain volumes that relies on a quantitative direct measurement of risk rather than categorical stratification by family history. This method, known as genetic risk scoring (GRS), uses risk alleles derived from genome-wide association studies (GWAS) studies to quantify the common risk allele burden carried by individuals for a given disorder based on the average number of independent risk alleles, weighted by their effect size. In the present study, we aimed to investigate the association between the volumes of brain regions previously shown to be abnormal in SCZ and BD (that is, thalamus, amygdala, hippocampus, globus pallidus, caudate and lateral ventricles) and GRS for both these disorders in a large sample of healthy participants with no history of mental disorders and free of any psychotropic medication. Assuming that structural brain abnormalities reported in BD and SCZ are consequences of genetic risk factors that are common to both disorders, we predict the volume of these subcortical areas to be associated with the shared genetic risk for both disorders, and less so with their distinct genetic risk. The fact that the sample only includes participants with no personal history of BD or SCZ precludes any secondary influences of disease course or treatment on brain volume.

MATERIALS AND METHODS

Participants

Brain scans used in this study were obtained from a repository of neuroimaging and genetic data obtained between 2009 and 2014 from healthy subjects recruited at Cardiff University Brain Research Imaging Centre (CUBRIC). The original sample consisted of 319 individuals that contributed neuroimaging and genetic data. Participants were recruited if they had no current or past history of psychiatric disorders according to clinical screening, were aged between 18 and 55, and had no history of neurological or medical conditions that could have affected brain anatomy or incurred a scanning risk (for example, head trauma, epilepsy, cardiac conditions).

Genotyping and quality control

Genomic DNA was obtained from saliva using Oragene OG-500 saliva kits (DNA Genotek, Kanata, ON, Canada). Genotyping was performed using custom Illumina HumanCoreExome-24 BeadChip genotyping arrays that contained probes for 570,038 genetic variants (Illumina, San Diego, CA). Quality control was implemented in PLINK.16 Individuals were excluded for any of the following reasons: (1) no match between reported and molecular sex; (2) genetic relatedness of up to third degree relatives as ascertained using identity by descent; (3) genotyping completeness < 97%; (4) and non-European ancestry. The latter was detected as outliers in iterative EIGENSTRAT analyses of a linkage disequilibrium pruned data set.17 Single nucleotide polymorphisms (SNPs) were excluded for any of the following reasons: (1) minor allele frequency < 1%; (2) genotype call rate < 98%; and (3) Hardy-Weinberg equilibrium P-value < 1e-04. Genotypes were imputed using the pre-phasing/imitation stepwise approach implemented in IMPUTE2/SHAPING18,19 and 1000 Genomes (December 2013, release 1000 Genomes haplotypes Phase I integrated variant set) as the reference data set.

After quality control, the sample was reduced to 274 participants (195 (71.4%) females, mean age 24.77 (s.d. 6.86)). About 2,968,832 genotyped SNPs passed quality controls and resulted in a data set of 74,133,342 imputed SNPs.

MRI data acquisition and processing

All magnetic resonance imaging (MRI) data were acquired in a GE Sigma HD × 3T scanner (GE Healthcare, Milwaukee, WI, USA) at CUBRIC. Anatomical images of the brain consisted of 3D fast spoiled gradient echo images obtained at TR = 7.9 ms, TE = 3.0 ms, inversion time = 450 ms, flip angle = 20°, acquisition matrix = 256 (AP) × 192 (LR) × 172 (SI), 1 mm isotropic voxels.

Brain images were automatically segmented using FreeSurfer software (http://surfer.nmr.mgh.harvard.edu) and the resulting outputs quality controlled following a publically available protocol from ENIGMA (http://enigma.ini.usc.edu/). Whenever a region-of-interest (ROI) was detected as inadequately segmented, its metric was declared missing and excluded from the analysis.

Genetic risk score

GRS methodology follows the procedure described by the International Schizophrenia Consortium.11 We calculated GRS using the results from four GWAS as our training data sets: (1) SCZ and BD cases versus controls (GRS-SCZ&BD);20 (2) SCZ cases versus BD cases (GRS-SCZvsBD);20 (3) SCZ cases versus controls (GRS-SCZ);21,22 and (4) BD cases versus controls (GRS-BD).22,23 For the GRS-SCZ and GRS-BD, we used results generated by the Cross-Disorder Group of the Psychiatric Genomics Consortium (PGC),22 which removed any overlapping controls from the data sets, ensuring the data sets were completely independent. Despite the existence of recent larger GWAS data for SCZ, for consistency we calculated the GRS-SCZ from the initial iterations of the PGC data for SCZ.22 The main focus of our analysis are the composite scores GRS-SCZ&BD and GRS-SCZvsBD and these are only available from the initial iterations of the PGC data; likewise, currently GRS-BD can only be obtained from the initial iteration of the PGC data.

For all analyses, SNPs were removed if they had a low minor allele frequency (MAF < 0.01), and were subsequently pruned for linkage disequilibrium using the (r² < 0.25) clumping function (—clump) in PLINK16 removing SNPs within 500 kb (—clump-kb) and r² > 0.25 (—clump-r2) with a more significantly associated SNP. We used the score command in PLINK to calculate GRS,16 which were calculated by summing the number of susceptibility alleles of each index SNP weighted by the logarithm of the SNP odds ratios. Six P-value thresholds (P1 < 1 × 10⁻⁵, 1 × 10⁻⁴, 0.01, 0.1, 0.3, 0.5) for SNP association were used.

Association analyses

All subcortical volumes (averaged left and right hemispheres) and GRS considered here followed the normal distribution. GRS were entered as regressors of interest in linear regression analyses—after covariates have been entered into the model—with gray matter volume of each ROI as dependent variable. Age at scan only correlated with the volume of the lateral ventricles and was therefore only included as covariate in the analyses for this ROI. Gender and intracranial volume showed significant association with volume of all the ROIs considered here and were included as covariates in all subsequent analyses. According to our hypotheses, we investigated first the association of GRS-SCZ&BD and GRS-SCZvsBD with volume of the preselected ROIs. Where significant effects were found, we investigated the association with the disorder-specific GRS (that is GRS-SCZ and GRS-BD) to ascertain that the effect was not driven by the sole association with one of the phenotypes. Based on Sham and Purcell’s24 recommendations for multiple testing correction in dependent tests, we applied a post hoc correction for multiple comparisons by performing 10,000 permutations of each linear regression analysis resulting in a nominal P < 0.05. These were performed using R.25 The permuted P-value was calculated as the total number of times a permutation resulted in a P-value less than the observed P-value, divided by the number of permutations. If the permuted P-value was P < 0.05, then we considered the significance of this effect to be of corrected P-value.
The GRS-SCZvsBD only showed significant association—negative correlation—when calculated at $P < 1 \times 10^{-5}$ with volume of the amygdala (Table 1 and Figure 1). Analyses with the disease-specific scores revealed that volume of the amygdala was negatively associated with GRS-BD but not with GRS-SCZ (Table 2).

### Table 1. Results from association between risk profile score (RPS) for schizophrenia and bipolar disorder cases versus controls (SCZ&BD), schizophrenia cases versus bipolar disorder cases (SCZvsBD) and total volume in selected regions-of-interest

| Region         | Candidate β (P) $\Delta R^2$ | Lateral ventricle β (P) $\Delta R^2$ | Thalamus β (P) $\Delta R^2$ | Amygdala β (P) $\Delta R^2$ | Hippocampus β (P) $\Delta R^2$ | Globus pallidus β (P) $\Delta R^2$ |
|----------------|-------------------------------|--------------------------------------|-----------------------------|-------------------------------|-------------------------------|----------------------------------|
| SCZ vs BD      |                               |                                      |                             |                               |                               |                                  |
| RPS 1×10^{-5}  | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000                | 1.0000 (0.000) 0.000        | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000             |
| SCZ vs BD      |                               |                                      |                             |                               |                               |                                  |
| RPS 1×10^{-4}  | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000                | 1.0000 (0.000) 0.000        | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000             |
| RPS 0.1        | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000                | 1.0000 (0.000) 0.000        | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000             |
| RPS 0.5        | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000                | 1.0000 (0.000) 0.000        | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000          | 1.0000 (0.000) 0.000             |

### Discussion

This study aimed to investigate the relationship between composite measures of genetic risk for SCZ and BD with the volume of subcortical brain structures that have previously been shown to differ between cases and controls in clinical samples of SCZ and BD, in a sample of healthy participants. Our results showed the volume of the globus pallidus to be associated with the genetic risk for both these disorders. Interestingly, the predictive value—change in variance explained ($\Delta R^2$)—of the combined SCZ&BD GWAS on the volume of this structure was larger than the predictive value of the risk for each disorder considered separately. This suggests that the volume of the globus pallidus is associated with genetic variants that influence risk for both SCZ and BD, rather than with non-shared genetic variants. Contrary, the volume of the amygdala was only associated with genetic risk for BD; although in this case, fewer associations with GRS calculated at different $P$-values were found, making this finding less robust.

Previous research has shown the globus pallidus to be larger in BD and SCZ patients compared with healthy controls. Here, we show volume of this brain structure is negatively associated with genetic risk for these disorders in a sample of healthy participants. Given that our participants were un-medicated and did not suffer from any psychiatric condition, this association could not be mediated by secondary effects of these disorders, or by the effect of psychotropic medication. Moreover, we show that the volume of this brain structure is associated with that fraction of genetic risk that is shared across BD and SCZ. Interestingly, we found an inverse relationship between genetic risk for these disorders and the volume of the globus pallidus; that is, the higher the risk added by common genetic variants the smaller the volume of this structure. Antipsychotic medication has shown to increase the volume of basal ganglia structures. The ENIGMA consortium results for BD show enlarged volume of the globus pallidus in patients taking typical antipsychotics compared with healthy controls and also compared with patients under other class of drugs/no-drugs. Similarly, those taking atypical antipsychotics showed enlarged volume than healthy controls and patients under other class of drugs/no-drugs, albeit in this case not reaching statistical significance. The ENIGMA SCZ group also showed that volume of the globus pallidus was positively associated with illness duration. Summarizing, the present results show volume of the globus pallidus to be associated with the shared genetic risk for BD and SCZ; the fact that we find an inverse relationship while clinical studies show enlargement in clinical samples relative to controls could be explained by the influence of factors like illness duration or antipsychotic medication. This study does not directly compare the results with other studies, but differences between clinical and control samples, or studies of joined clinical and healthy samples, where many factors associated with the pathology might conceal the results.

Our results also suggest amygdala volume to be negatively associated with genetic risk for BD, but not for SCZ. Although in this case the association follows the expected direction—that is, decreasing volume as genetic risk increases—the lack of association with genetic risk for SCZ or with the added risk for both disorders was unexpected. Previous research has consistently shown reduced amygdala volume in SCZ patients compared with controls, with these studies presenting larger effect sizes than equivalent studies in BD. Unlike in the analyses with globus pallidus, though, the significant association between
Globus pallidus

GRS-SCZ&BD \(P_T = 0.5\)

GRS-SCZvsBD \(P_T = 1 \times 10^{-5}\)

Amygdala

GRS-SCZ&BD \(P_T = 0.3\)

GRS-SCZvsBD \(P_T = 0.1\)

GRS-SCZvsBD \(P_T = 0.01\)

Figure 1. Scatterplots representing the significant association between volume of the globus pallidus and the shared genetic risk scoring for schizophrenia and bipolar disorder calculated at different \(P_T\) levels (top row), and between volume of the amygdala and the non-shared genetic risk scoring for schizophrenia and bipolar disorder obtained at \(P_T = 1 \times 10^{-5}\) (bottom row). BD, bipolar disorder; GRS, genetic risk score; SCZ, schizophrenia.

Table 2. Results from association between risk profile score (RPS) for schizophrenia (SCZ) cases versus controls and bipolar disorder (BD) cases versus controls with total volume in amygdala and globus pallidus

| RPS \(P_T\) | Amygdala \(\beta\) (\(P\)) \(\Delta R^2\) | Globus pallidus \(\beta\) (\(P\)) \(\Delta R^2\) |
|------------|-----------------|-----------------|
| SCZ        |                 |                 |
| 1 \times 10^{-5} | -0.037 (0.446) 0.001 | 0.039 (0.434) 0.002 |
| 1 \times 10^{-4} | -0.010 (0.837) < 0.001 | -0.004 (0.943) < 0.001 |
| 0.01       | -0.068 (0.169) 0.005 | -0.142 (0.004) 0.020 |
| 0.1        | -0.018 (0.714) < 0.001 | -0.095 (0.056) 0.009 |
| 0.3        | 0.004 (0.937) < 0.001 | -0.104 (0.039) 0.11 |
| 0.5        | 0.002 (0.974) < 0.001 | -0.115 (0.022) 0.013 |
| BD         |                 |                 |
| 1 \times 10^{-5} | -0.142 (0.004) 0.020 | -0.050 (0.314) 0.002 |
| 1 \times 10^{-4} | -0.086 (0.079) 0.007 | -0.020 (0.694) < 0.001 |
| 0.01       | -0.098 (0.045) 0.010 | -0.125 (0.012) 0.016 |
| 0.1        | 0.017 (0.724) < 0.001 | -0.102 (0.042) 0.010 |
| 0.3        | -0.016 (0.740) < 0.001 | -0.066 (0.188) 0.004 |
| 0.5        | -0.043 (0.376) 0.002 | -0.066 (0.185) 0.004 |

\(\beta\), beta value for the RPS in the regression equation after covariates have been included; \(P\), significance level associated to the \(\beta\) value, all \(P\)-values reported are nominal; \(\Delta R^2\), change in variance explained added by the RPS. Bold results signify those with nominal \(P\)-value < 0.05.

The report presented here has some strengths and weaknesses that should be noted. Our sample is large for a study homogeneous in terms of recruitment methods, exclusion criteria, magnet, MRI acquisition protocol, data pre-processing, analysis and quality control. The extent to which this affords a relative advantage over larger, but much more heterogeneous, meta-analyses such as those by ENIGMA is, however, not clear. Future researches with similarly homogeneous but larger samples are necessary to validate the present findings. For example, considering the average correlation found here between volume of lateral ventricles and the GRS-SCZ&BD \((r = 0.1)\), and to maintain a nominal \(P\)-value of 0.05 and a power of 0.85, a sample size of \(n = 717\) would be required for that to be significant (StatsToDo). This is even more relevant with regard to our conclusion that most previously reported volume abnormalities observed in these structures in clinical studies comparing patients and controls are not a consequence of disorder liability. Whether they reflect environmental exposures on the causal pathway to disease, or whether they are consequences of the disorder cannot be answered by the present study. The fact that some of these abnormalities have been shown in non-affected relatives of SCZ or BD patients, led to the conclusion that these were associated with genetic risk. However, these might well still be explained by shared environmental factors between patients and their close relatives. For example, Boos et al.27 showed in a meta-analysis that like patients, non-affected SCZ relatives showed reduced hippocampal volume compared with healthy controls. However, it has been recognized that the family environment of SCZ patients presents with high levels of stress,28 and that exposure to stress may contribute to reductions in hippocampal volume via hypercortisolemia.29 Therefore, reduced hippocampal volume in SCZ patients and their relatives compared with healthy controls with no family history of SCZ could be explained by differences in the levels of stress to which these groups are exposed throughout their lives, rather than to genetic factors.

Globus pallidus and amygdala volume was limited to one GRS value (that is, \(P_T = 1 \times 10^{-5}\)), and to only two GRS values when using the GRS-BD scores (that is, \(P_T = 1 \times 10^{-3}\) and \(P_T = 0.01\)). The limited number of significant associations in this case could suggest the possibility of these representing a type I error, and further replication would be required before firm conclusions can be drawn.

The lack of association between most subcortical volumes considered here and GRS for SCZ and BD suggests that the abnormalities observed in these structures in clinical studies comparing patients and controls are not a consequence of disorder liability. Whether they reflect environmental exposures on the causal pathway to disease, or whether they are consequences of the disorder cannot be answered by the present study. The fact that some of these abnormalities have been shown in non-affected relatives of SCZ or BD patients, led to the conclusion that these were associated with genetic risk. However, these might well still be explained by shared environmental factors between patients and their close relatives. For example, Boos et al.27 showed in a meta-analysis that like patients, non-affected SCZ relatives showed reduced hippocampal volume compared with healthy controls. However, it has been recognized that the family environment of SCZ patients presents with high levels of stress,28 and that exposure to stress may contribute to reductions in hippocampal volume via hypercortisolemia.29 Therefore, reduced hippocampal volume in SCZ patients and their relatives compared with healthy controls with no family history of SCZ could be explained by differences in the levels of stress to which these groups are exposed throughout their lives, rather than to genetic factors.
lack of association in our study could simply be a consequence of limited statistical power. Also, as previously stated, due to the lack of an equivalent GWAS for BD, we based our GRS calculations on the initial iterations of the PGC data for SCZ.21 Since GRS estimated from larger GWAS are meant to be more accurate, our results will require replication once the latest GWAS for BD results are available. Also, these new GRS would be expected to present lower variability within healthy control samples, and again are likely to require larger sample sizes to be powered to reveal any significant association.

In summary, our study reports an association between volume of the globus pallidus and genetic risk for SCZ and BD, and suggests this is driven by alleles that confer risk for both disorders. This result adds further to the possibility that SCZ and BD share a common genetically driven etiological mechanism in line with the dimensional focus of the Research Domain Criteria.20 However, we also found a potential distinct association between genetic risk for these disorders and amygdala volume, which will also support the existence of distinct genetically driven etiological mechanism between SCZ and BD. The latter result, though, was less robust and requires more cautious consideration. Importantly, our study also questions whether other repeatedly reported volumetric abnormalities (for example, enlarged lateral ventricles, reduced thalamus) are associated with genetic risk for SCZ and/or BD, rather than being a consequence of the disease or of the exposure to environmental factors.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
We thank Prof Mick O’Donovan for his fruitful comments on this project’s results and Valentina Escott-Price for her advise on statistical aspects. We are also grateful to the National Centre for Mental Health (NCMH) in Cardiff for technical support and funding of the genotyping, and the Neuroscience and Mental Health Research Institute (NMHRI) at Cardiff University for support with the genetic imaging database. DL and KET were supported by the MRC grant reference MR/K004360/1: Behavioural and neurophysiological effects of schizophrenia risk genes: a multi-focus, pathway based approach.

REFERENCES
1 McDonald C, Zanelli J, Rabe-Hesketh S, Ellison-Wright I, Sham P, Kalindindi S et al. Meta-analysis of magnetic resonance imaging brain morphometry studies in bipolar disorder. Biol Psychiatry 2004; 56: 411–417.
2 Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 2008; 65: 1017–1032.
3 Amone D, Cavanagh J, Gerber D, Lawrie SM, Elbeimeer KP, McIntosh AM. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br J Psychiatry 2009; 195: 194–201.
4 Hibar DP, Westfyle LT, van Erp TG, Rasmussen CD, Leonardo UK, Haukvik C et al. ENIGMA Bipolar Disorder working group findings from 1747 cases and 2615 controls. Paper presented at Organization for the Human Brain Mapping Annual Meeting; 8–12 June 2014; Munich, Germany.
5 Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000; 157: 16–25.
6 van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Adreassen OA et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry; e-pub ahead of print 2 June 2015; doi: 10.1038/mp.2015.118.
7 Ellison_Wright I, Bullmore ET. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophr Res 2010; 117: 1–12.
8 Rimol LM, Hartberg CB, Nenväg R, Fennema-Notestine C, Hagler DJ Jr, Pung CJ et al. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. Biol Psychiatry 2010; 68: 41–50.
9 Tamminga CA, Ilevla EI, Keshavan MS, Pearlson GD, Clementz BA, Witte B et al. Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry 2013; 170: 1263–1274.
10 Vöhringer PA, Barrolihat SA, Ameno A, Reale ML, Alvear K, Vergne D et al. Cognitive impairment in bipolar disorder and schizophrenia: a systematic review. Front Psychiatry 2013; 4: 87.
11 International schizophrenia consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748–752.
12 Cross-disorder group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 45: 984–994.
13 McIntosh AM, Job DE, Moorhead TW, Harrison LK, Forrest K, Lawrie SM et al. Voxel-based morphometry of patients with schizophrenia or bipolar disorder and their unaffected relatives. Biol Psychiatry 2004; 56: 544–552.
14 McDonald C, Marshall N, Sham PC, Bullmore ET, Schulze K, Chapple B et al. Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Am J Psychiatry 2006; 163: 478–487.
15 Oertel-Knochel V, Knöchel C, Matura S. Cortical-basal ganglia imbalance in schizophrenia patients and unaffected first-degree relatives. Schizophr Res 2012; 138: 120–127.
16 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
17 Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal component analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904–909.
18 Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda) 2011; 1: 457–470.
19 1000 Genome Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56–65.
20 Ruderfer DM, Fanous AH, Ripke S, McQuillan A, Amdur RLSchizophrenia Working Group of PGCet al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry 2014; 19: 1017–1024.
21 Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011; 43: 969–976.
22 Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011; 43: 977–983.
23 Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with a shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381: 1371–1379.
24 Sham PC, Purcell SM. Statistical power and significance testing in large-scale genetic studies. Nat Rev Genet 2014; 15: 335–346.
25 R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria, 2012.
26 Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med 2009; 39: 1763–1777.
27 Boos HB, Aleman A, Cahn W, Hulshoff P, Kahn RS. Brain volumes in relatives of patients with schizophrenia. Arch Gen Psychiatry 2007; 64: 297–304.
28 Walder DJ, Faraone SV, Glatt SJ, Tsuang MT, Seidman LJ. Genetic liability, prenatal health, stress and family environment: risk factors in the Harvard Adolescent Family High Risk for schizophrenia study. Schizophr Res 2014; 157: 142–148.
29 Lawrie SM, McIntosh AM, Hall J, Owens DGC, Johnstone EC. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull 2008; 34: 330–340.
30 Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167: 748–751.